Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01970176 · ClinicalTrials.gov registry record · Phase 1

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

A Phase 1 study of Renal Impairment and Cardiomyopathy, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01970176: Completed Phase 1 study of Renal Impairment and Cardiomyopathy, sponsored by Mayo Clinic.

NCT01970176 is a Phase 1 study of Renal Impairment and Cardiomyopathy that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01970176, a Phase 1 study of Renal Impairment and Cardiomyopathy, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction.

Primary Outcome

Change in total urinary sodium excretion as measured by MEq/min

Interventions

  • DRUG Placebo
  • DRUG Tadalafil

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-01-09
Est. Completion 2019-09
Phase Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT01970176 record still lists

NCT01970176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (41% lower).

The record links to 2 conditions, with Renal Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01970176 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT01970176 about?

NCT01970176 is a clinical study titled "Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)". To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction...

What is the current status of trial NCT01970176?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-01-09. Estimated completion is 2019-09.

What conditions does trial NCT01970176 study?

This clinical trial studies the following conditions: Renal Impairment, Cardiomyopathy.

What interventions are being tested in trial NCT01970176?

The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).

Who is sponsoring clinical trial NCT01970176?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01970176 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01970176's enrollment target sits among peer trials

20 27th of 32 higher than 6 of 32 other Renal Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01970176, the US trial registry maintained by the National Library of Medicine. NCT01970176 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.